WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2024 Issue has been successfully launched on 1 FEBRUARY 2024.

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR February 2023 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

ACUTE EFFECTS OF PSILOCYBIN IN NON-CLINICAL POPULATIONS: A SYSTEMATIC REVIEW OF CLINICAL TRIALS

Paloma Garcia, BS Candidate, Michael Wang, MD Candidate, Rachel Pearl, MD, Jonathan Dang, MD, Salma Abdelmoteleb, MD, Itai Danovitch, MD, MBA and Waguih William IsHak, MD, FAPA*

ABSTRACT

Objective: Psilocybin has been researched as a treatment for a variety of psychiatric disorders, with increasinglyrobust evidence for its efficacy in treating depressive disorders. As psilocybin gains legitimacy for clinical use, weforesee a climate in which there will be increased accessibility among the general population. The purpose of thispaper is to review the literature concerning the acute effects of psilocybin in non-clinical populations to answerthe following questions: (a) What is the impact of psilocybin in non-clinical populations in the acute phase? (b)What are the acute effects of different psilocybin doses in non-clinical populations? Methods: FollowingPRISMA guidelines, studies published from January 1990 to December 2023 pertaining to the acute effects ofpsilocybin in non-clinical populations were identified from the PubMed database, using the keywords:?psilocybin‘ AND ?acute‘ OR ?immediate‘, AND ?effects‘ AND ?healthy‘ OR ?volunteer‘ OR ?non-clinical?. Twoauthors independently conducted a focused analysis and reached a final consensus on 32 studies that met thespecific selection criteria and passed the study quality checks. Results: Among the 32 studies of non-clinicalpopulations, 30 were clinical trials, and 2 were pooled analyses. Doses ranged between very low (less than5mg/70 kg), low (8-12 mg/70kg), medium (15-20mg/70kg), and high (22-30mg/70kg). Low doses of psilocybinwere found to induce altered states of consciousness and mystical experiences, which intensified with higherdoses. Studies showed that psilocybin is associated with dose-dependent cognitive impairments in domains suchas attention, inhibition, and memory as well as adverse effects such as transient increases in systolic and diastolicblood pressure, heart rate, and dose-dependent anxiety, fear, paranoia, fatigue, headache, and difficulty withconcentration. Conclusion: This review details a broad range of perceived benefits and risks associated withpsilocybin use in healthy volunteers. Specifically, we identified highly variable, dose-dependent effects onconsciousness, mysticism, affect, and cognition. Findings from our review indicate that the risks associated withpsilocybin use are relatively low. However, most studies in our review were conducted among volunteersassociated with mainstream demographics in industrialized communities. While psilocybin can be confirmed assafe for certain non-clinical populations, there is a need for further research among more diverse populations togeneralize these conclusions.

[Full Text Article] [Download Certificate]